Connection
David Raben to Hydroxamic Acids
This is a "connection" page, showing publications David Raben has written about Hydroxamic Acids.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.116 |
|
|
|
-
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 01; 21(7):1566-73.
Score: 0.116